盈喜藥明生物(02269.HK)曾漲9% 醫藥相關股逆揚 金斯瑞及復銳醫療漲6%及21%創上市新高
同業發盈喜，醫藥股普遍逆市上揚。藥明生物(02269.HK)發盈喜料中績多賺逾1.35倍以上，該股今天逆市重越10天及20天線(135.06元)，曾漲近9%高見143元，暫受制7月2日盤中所創上市高位148元，現造138.8元，回升5.7%，爲最強藍籌，成交增至2,041萬股。藥明康德(02359.HK)及藥明巨諾-B(02126.HK)回升2.3%及4.2%，曾分別高見187.5元(暫受制本月2日所創上市高位188元)及22.95元，後者股價重越10天線(22.18元)。
藍籌石藥(01093.HK)及中生製藥(01177.HK)四連升及三連升，最高見11.06元及7.31元，現造10.88元及7.24元，續升3.4%及3%，後者股價重越10天線(7.19元)。
四環醫藥(00460.HK)重越100天及10天線(2.83元及2.98元)，最多急漲13%至3.16元(暫受制20天線3.17元)，現造3.02元，回升9.8%，成交增至1.44億股。
昊海生科(06826.HK)重越10天線(108.4元)，最高見118.2元，現造113.3元，回升8.9%，成交增至186萬股。榮昌生物-B(09995.HK)重越100天、50天 及10天線(107.5-110.6元)，最高見112.5元，現造110.1元，回升5%。金斯瑞生物(01548.HK)三連升，股價高見40元再創紀錄高，現造39.8元，續升6.1%。聯邦製藥(03933.HK)曾一舉重越20天及100天線(6.22元及6.35元)，最高見6.41元，現造6.24元，回升2.6%。
亞盛醫藥-B(06855.HK)最高見53.8元，暫受制今年1月所創上市高位54.7元，現造52.95元，回升7%。君實生物(01877.HK)由半年低位連升第四天，最高見63.1元，現造61.6元，續升5.4%。開拓藥業-B(09939.HK)重越10天線(58.5元)，最高見60.6元，現造59.6元，回升6.1%。昭衍新藥(06127.HK)重越10天及20天線(117.26元及118.72元)，最高見133.2元，現造131.8元，急漲14%。
此外，復銳醫療科技(01696.HK)繼昨天整固後，今天股價再創上市新高，最高見28.85元，現造27.7元，急漲21%。微創醫療(00853.HK)重越10天及20天線(66.36元及67.25元)，最高見70.2元，現造69.8元，回升10%。海吉亞醫療(06078.HK)重越10天及20天線(95.45元及97.06元)，最高見98.35元，現造97.5元，回升6%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
